These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16522454)

  • 41. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
    Wasserman RL; Baker JW; Kim KT; Blake KV; Scott CA; Wu W; Faris MA; Crim C
    Ann Allergy Asthma Immunol; 2006 Jun; 96(6):808-18. PubMed ID: 16802768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products.
    Daley-Yates PT; Parkins DA; Thomas MJ; Gillett B; House KW; Ortega HG
    Clin Ther; 2009 Feb; 31(2):370-85. PubMed ID: 19302910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. No association of catastrophic events with Advair.
    Yancey SW; Knobil K; Kral K
    Am J Med; 2010 Oct; 123(10):e15; author reply e17. PubMed ID: 20920673
    [No Abstract]   [Full Text] [Related]  

  • 45. Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices.
    Metcalfe S; Moodie P
    J Allergy Clin Immunol; 2004 Mar; 113(3):568-9; author reply 569-71. PubMed ID: 15007365
    [No Abstract]   [Full Text] [Related]  

  • 46. Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall.
    Spahn J; Sheth K; Yeh WS; Stempel DA; Stanford RH
    J Allergy Clin Immunol; 2009 Dec; 124(6):1197-203. PubMed ID: 19910037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.
    Lipworth BJ; Fardon TC
    J Allergy Clin Immunol; 2004 Jan; 113(1):178; author reply 178-9. PubMed ID: 14713929
    [No Abstract]   [Full Text] [Related]  

  • 48. [Bronchial asthma in children].
    Nishima S
    Arerugi; 2011 Jan; 60(1):10-5. PubMed ID: 21346402
    [No Abstract]   [Full Text] [Related]  

  • 49. The effects of combination treatment with a long-acting beta2-agonist and a corticosteroid on salivary flow rate, secretory immunoglobulin A, and oral health in children and adolescents with moderate asthma: a 1-month, single-blind clinical study.
    Sag C; Ozden FO; Acikgoz G; Anlar FY
    Clin Ther; 2007 Oct; 29(10):2236-42. PubMed ID: 18042480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA panel: ban 2 popular asthma drugs.
    Kuehn BM
    JAMA; 2009 Jan; 301(4):365-6. PubMed ID: 19176431
    [No Abstract]   [Full Text] [Related]  

  • 51. Benefits of combination therapy on exacerbations in nonsmoking patients with asthma.
    Jackson C; Lipworth B
    J Allergy Clin Immunol; 2008 Mar; 121(3):780; author reply 780. PubMed ID: 18243291
    [No Abstract]   [Full Text] [Related]  

  • 52. Use of fluticasone in asthma.
    Lipworth BJ
    Chest; 2000 Feb; 117(2):611-3. PubMed ID: 10669719
    [No Abstract]   [Full Text] [Related]  

  • 53. [Measurement of peak inspiratory flow with asthma: effect of inhaled beta2-stimulant].
    Shimizu K; Yamazaki Y; Kishimoto N; Tada S; Ueda N; Fujita J; Kamei T; Okada H; Arakawa Y; Nakamura H
    Nihon Kokyuki Gakkai Zasshi; 2005 Apr; 43(4):216-20. PubMed ID: 15966367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group.
    Boulet LP; Cowie R; Johnston P; Krakovsky D; Mark S
    J Asthma; 1995; 32(6):429-36. PubMed ID: 7592246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Practice. Mild asthma.
    Bel EH
    N Engl J Med; 2013 Aug; 369(6):549-57. PubMed ID: 23924005
    [No Abstract]   [Full Text] [Related]  

  • 56. The pressurized metered dose inhaler (pMDI) remains the most commonly prescribed device for the delivery of inhaled asthma medications.
    Braunstein G; Sharma R
    Respir Med; 2000 Jun; 94 Suppl B():S1-2. PubMed ID: 10919678
    [No Abstract]   [Full Text] [Related]  

  • 57. [Inhalation combination therapy in chronic obstructive lung disease. TRISTAN-study].
    Seeger W; Schulz R
    Internist (Berl); 2004 Jun; 45(6):727-8. PubMed ID: 15138641
    [No Abstract]   [Full Text] [Related]  

  • 58. [Fixed-dose combination of proven active ingredients in new inhaler].
    Koczorek M
    Med Monatsschr Pharm; 2014 Sep; 37(9):341-2. PubMed ID: 25282752
    [No Abstract]   [Full Text] [Related]  

  • 59. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
    Foster JM; Usherwood T; Smith L; Sawyer SM; Xuan W; Rand CS; Reddel HK
    J Allergy Clin Immunol; 2014 Dec; 134(6):1260-1268.e3. PubMed ID: 25062783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment.
    Westmeier R; Steckel H
    J Pharm Sci; 2008 Jun; 97(6):2299-310. PubMed ID: 17879293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.